X

Drug Profile

M 031

Alternative Names: GalC^M6P; M-031

Latest Information Update: 12 Apr 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator M6P Therapeutics
Class Enzymes; Recombinant proteins
Mechanism of Action Enzyme replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Discontinued Globoid cell leukodystrophy

Most Recent Events

12 Apr 2023 Discontinued - Preclinical for Globoid cell leukodystrophy in USA (unspecified route) (M6P Therapeutics pipeline, April 2023)
04 Feb 2021 M 031 is available for licensing as of 04 Feb 2021
28 Jan 2021 Recombinant enzyme replacement therapies received rare paediatric disease designations for Lysosomal storage diseases in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com